BridgeBio could be an acquisition target, but current financial challenges and competition suggest a "Hold" rating until ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...

Acoramidis has been cleared under the Attruby brand name as an oral therapy to reduce cardiovascular death and cardiovascular-related hospitalisation in adults with ATTR-CM, a progressive disease ...

BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...

BridgeBio Pharma said it is fully financed to launch its cardiomyopathy treatment Attruby and read out its phase 3 clinical trials, which are fully enrolled. Shares rose 8.6% to $31.58 in morning ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

Syed’s analysis suggests that the current market consensus for Attruby’s 2025 sales is underestimated, with potential for this figure to increase as the drug captures new and switch patients.

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled ...